These 3 Dividend Stocks Have Crushed the Market This Year. Here’s Why They Are Still Buys

By: www.fool.com|11/16/2026 23:40:02

Artificial intelligence (AI) stocks continue dominating headlines on Wall Street. That probably won't change anytime soon. But investors shouldn't be so distracted by the AI revolution that they forget there are attractive investment opportunities elsewhere. Consider the following three healthcare dividend stocks: AbbVie (ABBV -0.16%), Gilead Sciences (GILD -0.30%), and Becton, Dickinson (BDX -0.71%). All three have crushed broader equities this year, and they still have plenty of upside ahead for investors willing to stay the course. Read on to find out more.

Image source: Getty Images.

  1. AbbVie

AbbVie did not perform well in the first four months of the year, but it has recovered, and its shares are now up 29% to date, while the S&P 500 has gained 10%. There are several reasons behind the drugmaker's strong performance, perhaps none more important than its two biggest growth drivers, Skyrizi and Rinvoq. These two immunology medicines are performing better than management -- and Wall Street -- expected.

Considering they won't lose patent protection anytime soon, and AbbVie will face no other major loss of patent exclusivity through the end of this decade, we can expect consistent revenue and earnings growth over the medium term. Still, Skyrizi and Rinvoq will eventually face patent cliffs, with the former perhaps starting around 2033. The good news is AbbVie is preparing for that.

AbbVie has strengthened its immunology pipeline through an acquisition and is looking to enter the fast-growing weight-loss market. Further, legacy products, especially its Botox franchise, should perform well over the long term. AbbVie's excellent underlying business will help support its dividend program.

The company is a Dividend King, one of the corporations that have increased their payouts for at least 50 consecutive years. It would take something catastrophic for AbbVie to suspend or decrease its dividends. Until then, expect regular dividend increases alongside solid returns from the company.

  1. Gilead Sciences

Gilead Sciences' shares have gained 37% this year on the back of improving financial results and solid clinical and regulatory progress. The biotech leader still makes most of its money from its HIV franchise, with medicines like Biktarvy doing much of the heavy lifting. And even though Veklury, a coronavirus medicine, is harming top-line growth, the company has performed well.

Gilead Sciences' third-quarter product sales grew 13% year over year -- its fastest growth rate in this category in over a decade -- to $8.29 billion. Total revenue was $8.30 billion, up almost 7% compared to the year-ago period. Product sales excluding Veklury jumped 16% year over year.

So, as Veklury continues to fade into insignificance, Gilead should record stronger top-line growth, especially as it has strengthened its HIV and oncology businesses this year with new approvals and important label expansions. The biotech giant's outlook appears stronger than it has been in a while, and its dividend program remains attractive. Gilead Sciences offers a forward yield of 2%, and it has increased its payouts by 74.5% over the past 10 years.

  1. Becton, Dickinson

Becton, Dickinson, a medical technology company, is finally bouncing back after several challenging years. Shares are up 43% to date. One reason for the company's strong performance is its excellent financial results. In the fourth quarter of its fiscal year 2026, which ended Sept. 30, Becton, Dickinson's revenue increased by 5.4% year over year to $5.3 billion. Adjusted earnings per share rose 27.3% year over year to $4.15.

That's a strong performance for the healthcare giant. Another factor behind Becton, Dickinson's results is that it is benefiting from the soaring demand for GLP-1 products and should continue to do so over the medium term.

Growing demand for injectable diabetes and weight-loss medicines is driving significant increases in sales of prefillable syringes and self-injection devices for GLP-1 drugs. With the GLP-1 market projected to expand rapidly over the next five to 10 years, this tailwind may be just starting for Becton, Dickinson.

Meanwhile, the company's underlying business outside of that is resilient and highly predictable. Becton, Dickinson generates most of its revenue from recurring consumables. Finally, Becton, Dickinson is an excellent dividend stock. It is also a Dividend King with a streak of 55 consecutive payout increases.

-- Price

--
--
--

This content is provided for general informational purposes only and doesn't constitute financial, investment, legal, or tax advice. Any events, rewards, online promotions, or related information mentioned herein should not be considered a recommendation, solicitation, or invitation to purchase, sell, trade, or otherwise deal in any crypto assets. Crypto assets are highly volatile and may result in loss. The availability of WEEX services, products, and related events may vary by region. You are responsible for ensuring that your participation is in accordance with applicable local laws and regulations.

You may also like

iconiconiconiconiconiconiconiconicon
Customer Support:@weikecs
Business Cooperation:@weikecs
Quant Trading & MM:[email protected]
VIP Program:[email protected]